X-Mind Prime is the latest addition to ACTEON’s panoramic and CBCT digital imaging product line. It blends cutting-edge technology with ease of use in a compact design. With X-Mind Prime, high tech is at your fingertips with tools for accurate diagnosis and complete treatment planning.

X-Mind Prime combines 2D and 3D technologies. Using a single sensor, the practitioner can quickly and easily switch between modes. With 24 panoramic and 32 CBCT options, X-Mind Prime covers many clinical applications including implantology, endodontics, TMJ and sinus imaging. Practitioners can also scan 3D objects such as stone models and impression materials, opening up a whole range of new possibilities.

ACTEON Imaging Suite (AIS) software which is Windows and Mac compatible, provides advanced functionality. Intuitive image handling and state-of-the-art tools to simplify implant planning. In addition, customized reports improve patient communication.

X-Mind Prime is a lightweight and compact system that can fit into virtually any dental office. With its intelligent, wall-mounted design, the unit takes up zero floor space. Because the unit is delivered preassembled to the office, it can be installed by a single technician in under an hour, so it is up and running and does not interfere with office production.

Katy Kjartanson, General Manager of ACTEON North America said, “With the addition of X-Mind Prime, ACTEON shows that it has the capacity for innovation and the expertise to become a leader in dental imaging.”

Come see the new X-Mind Prime in person at the CDA Presents meeting in Anaheim at booth 1352

See more at: https://www.acteongroup.com/us/

DMG is proud to support the University of North Carolina Adams School of Dentistry with their recent donation of a toothbrush simulation testing machine.

Learn more about the UNC Adams School of Dentistry

“A critical key to our ability to bring our customers and their patients the most effective and safest materials possible is to support independent research at such pioneering institutions as UNC’s Adams School of Dentistry, which is renowned for its dental materials research,” said George Wolfe, President DMG America.

"We are incredibly grateful for the generosity of DMG,” said Scott S. De Rossi, DMD, MBA, dean of the University of North Carolina at Chapel Hill Adams School of Dentistry. “It is because of contributions like these that we are able to work toward our ultimate goal of becoming the global model for oral health education, in care and discovery."

DMG’s goal is to streamline the lives of dental professionals by producing premium quality dental materials that put their customers in a better position for clinical, operational and financial success. The company’s commitment to innovation is fostered by its strong collaborative relationships with many partners, including:

• Dental schools

• Private educational and research organizations

• Product testing facilities

• Leading dental practitioners and influencers

The need for a toothbrush simulation testing machine was first discussed in a meeting between Dr. Taiseer Sulaiman, Assistant professor, Division Director of Operative Dentistry and Biomaterials, Department of Restorative Sciences at the UNC Adams School of Dentistry, and Dr. Susanne Effenberger, DMG Head of Clinical Research, during her spring 2018 tour of the dental school. Discussion topics also included an educational grant by DMG and two possible in-vitro studies to be conducted by Dr. Sulaiman’s Biomaterials Laboratory at the school to confirm the quality of the chemical properties of an innovative new DMG material for use in dental practices. In the fall of 2018, plans for both the educational grant and the donation of the tooth brush simulator were finalized, and two months later the agreement for the two research projects was finalized. The tooth brush simulation testing machine was delivered to the school in early 2019. Read more about DMG’s legacy of giving back.

“I would like to extend my sincere appreciation to DMG for their continuous support of research in our Biomaterials Laboratory at the UNC-CH Adams School of Dentistry,” said Dr. Sulaiman. “Their support allows us to provide clinicians with guidelines and recommendations that support newly introduced materials. Maximizing the clinical relevance of in-vitro testing may help bridge some of the gaps that are currently present. With machines like the toothbrush simulator, we can investigate many properties related to surface gloss, roughness and color stability. DMG understandsthe importance ofsupporting research institutions with such equipment, and of enabling researchers and clinicians to have a better understanding of dental materials with the ultimate goal of providing our patients the best care possible.”

For information about DMG and its category-defining products, please visit https://www.dmg-america.com/.

About DMG

DMG manufactures and distributes market-leading restorative materials and preventive products that are internationally recognized for their quality and innovation. Known for breakthrough material technology, including flagship products Luxatemp, LuxaCore Z Dual, and the revolutionary Icon resin infiltrant, DMG is committed to helping the dental profession meet its materials needs through innovation, collaboration and dedication. For more information about DMG products, or to find a sales representative, please visit online at https://www.dmg-america.com, or call (800) 662-6383.

Inside Dental Technology Editorial Advisory Board member Alexander Wünsche will participate next month in an ocean stand-up paddleboard (SUP) endurance event, Crossing for a Cure, to raise money for families of people with cystic fibrosis (CF).

The event will start in the Bimini district of the Bahamas and end in Lake Worth, Florida—a total of approximately 80 miles. The paddle will start around 1AM Saturday, June 15, and is expected to take 16 to 18 hours, though Wünsche hopes to finish in less time than that. Boats will accompany each group of four to five paddlers for safety and support.

Wünsche, who along with his wife, Danielle, co-owns Zahntechnique laboratory in Miami, Florida, has been an avid SUP enthusiast for several years. He has competed in races such as the recent Key West Classic, a 13-mile paddle.

“I’m not intimidated by the open ocean because I am used to it and I love it; I feel so connected when I am in the water,” he says. “However, I think everybody is a bit intimidated by the distance and time of this race.”

Each participant in Crossing for a Cure must raise at least $1,500 for a CF charity. Wünsche has reached that goal already but continues to seek more donations through his Alex Paddles 4 Life foundation. He has friends in his native Germany who have been impacted by CF, and he was inspired to support this particular cause by a documentary about a surfer with CF whose breathing improves when she is near saltwater.

“That never left my head,” Wünsche says. “I could not participate last year because of a scheduling conflict, but I made sure to mark it on my calendar for this year.”

To donate through Alex Paddles 4 Life, click here.

Seize the opportunity to connect and learn from other inspiring women leaders in the dental industry. Be Boundless wants to help you develop professionally by breaking your limiting beliefs and providing you with insight that will allow you to thrive in this ever-changing industry. Explore the possibilities of ultimate wellness and being the best version of you!

When: June 20-22, 2019, Thursday - Saturday

Attendee Cost: $450, Includes all food and events

Where: A-dec Headquarters - Newberg, OR

Attendee space is limited! Get $50 off your ticket price with promo code: 50OFF

Click here to view event schedule.

Charlotte, North Carolina, U.S.A, 01 April 2019 — Dentsply Sirona’s new TPH Spectra^® ST flow extends the benefits of our novel SphereTEC^® filler technology to flowable composites. Excellent chameleon blending enables 5 shades to cover the full VITA^®1 range, and flow-on-demand handling provides versatility across all traditional flowable indications. 

Dentsply Sirona’s latest innovation in composite filler technology, SphereTEC^®, was introduced to the dental industry in 2015, and to North America in 2017. Over 14 million composite restorations later, clinicians will now be able to enjoy SphereTEC benefits in all composite cases with the comprehensive TPH Spectra ST portfolio. Designed to perfectly complement TPH Spectra ST universal composite, new TPH Spectra^® ST flow Flowable Composite Restorative is characterized by this cutting-edge filler technology.

 SphereTEC  technology  enables TPH Spectra ST flow composite to excel in the areas that matter most to dentists: handling, esthetics, and durability. The spherical-shaped filler particles allow for excellent adaptation to cavity surfaces, and work together with smaller irregular-shaped filler particles in the material to achieve versatile, flow-on-demand-handling. Precise match of SphereTEC filler to the TPH Spectra ST flow resin matrix creates an excellent chameleon shade blending effect and a perfect match to TPH Spectra ST universal composite shades. The unique structure of SphereTEC fillers maximizes composite strength and durability, while their sub-micron primary particle size ensures excellent esthetics and polishability.

The new TPH Spectra ST flow composite brings enhanced simplicity and versatility to traditional flowable indications.  It uses five universal CLOUD shades A1 to A4 to cover the entire VITA^®1 Classic range, streamlining flowable composite inventory and ensuring highly esthetic clinical results thanks to their distinct chameleon effect. TPH Spectra ST flow composite also offers one bleach shade (BW), two opaque dentin shades (D1 and D3), and one translucent enamel shade (E1) to accommodate special cases.

Dentists can dispense this flowable composite using syringes or the Compula® Tips unit-dose option.  Syringe refills are packaged with 2 syringes (1.8g each) and 25 syringe tips, while Compula^® Tips refills contain 16 Compula^® Tips (0.25g each).

TPH Spectra ST flow composite will be available for purchase  from authorized distributors on April 8, 2019.   With this product introduction, dentists can simplify every restoration with the TPH Spectra ST family of composites, featuring SphereTEC filler technology:

·      TPH Spectra ST universal composite covers the most common cases,

·      TPH Spectra ST Effects composite simplifies complex anterior cases,

·      And now TPH Spectra ST flow composite provides efficient esthetic flowable versatility.

For further information about the new TPH Spectra ST flow composite, contact your local Dentsply Sirona Restorative representative, Dentsply Sirona customer service at 800-532-2855 (option 2) or visit https://www.dentsplysirona.com/TPHSpectraSTflow.

Hexagon’s Manufacturing Intelligence division announced it has broken ground on the construction of a new expansion project on a 5-acre site in Novi, MI. Slated for completion in the fall of 2019, the 88,000 sq. ft. building will house a technology showroom, a technical training center, and a 15,000 sq. ft. laboratory and calibration hub. The two-story office area will have glass walls and windows presenting an exceptional view of the nearly 11,000 sq. ft. Hexagon showroom and demonstration area from both levels. Expanding Hexagon's presence in the Midwest, the Center of Excellence will serve as a cornerstone to support advanced manufacturing in the region. Hexagon will consolidate all its Manufacturing Intelligence businesses in the greater Detroit area into a central location, which includes MSC Software, Production Software (formerly Vero Software), Q-DAS, and its metrology solutions portfolio. Employees from the AutonomouStuff and Safety Critical brands of Hexagon’s Positioning Intelligence division will also work from the new site.

The two-story property will meet or exceed all aspects of the current Michigan Uniform Energy code. The building design will incorporate lighting controls and sensors to reduce energy consumption and take advantage of exterior daylight to supplement office area lighting. Focused on the employee experience, the floor plan features open common office spaces and separate huddle areas to encourage collaboration and innovation. All interior spaces will be outfitted with new modern furniture designed for the various ways today’s employees work, whether on their own, in teams, or informal collaborations. Other employee amenities include a fitness gym, coffee bars, lounges, and a modern break room designed for multi-purpose functions including meetings, events, and every-day meals and refreshment breaks. A high-tech solutions provider, Hexagon is focused on providing an environment that empowers team work, problem solving, and a high level of productivity among formerly separate areas of the business. The new center will be finely appointed in the Hexagon style with its modern color scheme and other company design elements.

"This is an exciting project for us, as we will utilize our vast wealth of Hexagon technologies during the build process—from total stations for surveying to digital construction. Ultimately, this state-of-the-art facility reflects the next phase in Hexagon's own data-driven evolution across industries to shape smart change," states Angus Taylor, President and CEO of Hexagon Manufacturing Intelligence North America. "Our investment in this Center of Excellence allows us to consolidate our technology teams and put them into a 21st century workspace that will serve both customers and employees with the highest quality services and workplace environment."

With Cord Stähler, Dentsply Sirona is gaining a renowned expert in healthcare, life science, and diagnostics. He holds a PhD in Human Genetics and brings many years of experience in leadership roles with global companies. Based at Dentsply Sirona’s Bensheim site, he will be responsible for establishing a product development and innovation strategy for pioneering dental technology across all areas. In this capacity, he will report directly to CEO Don Casey.

"We are delighted to have Cord Stähler join us. His expertise makes him the ideal choice for consistently advancing our course of realigning our global strategy and raising our profile as a leading provider of innovative dental solutions," Casey explains.

Michael Geil, Managing Director at the Bensheim site says, "Cord Stähler's varied experience in technology management and company development is a huge asset for us. He will further strengthen the position of Bensheim as a location for innovation."

"I am looking forward to giving new impetus in a dynamic market environment at a global leader like Dentsply Sirona," Stähler comments.

Stähler joins Dentsply Sirona from Merck KGaA, where, most recently, he was Senior Vice President & Head of the Global Medical Device & Service Business in Geneva. In this role, he managed global business activities, such as product development, key account management, and customer training. He was also responsible for expanding the digital strategy of Merck Healthcare. Previously, Stähler held the position of CTO and Member of the Executive Committee at Siemens Healthcare in Erlangen and Berkeley, USA for five years, and was responsible for the technology base and innovation pipeline of the global healthcare unit. He also played a key role in designing and successfully implementing a strategic innovation and business development program.

As CTO and CEO, Stähler helped to establish several companies including an instrumentation company and a software development company in the field of genome analysis. He was a driving force behind the successful development of companies in Europe, the USA, and Asia. Throughout his career, the multi-award-winning company founder and researcher helped to develop more than 70 products, for which patents have been filed.

Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, reported record first quarter financial results from continuing operations. Note that results from continuing operations exclude contributions from Henry Schein’s former Animal Health business, which was spun off in February 2019 to form a new publicly traded company, Covetrus.

Net sales from continuing operations for the quarter ended March 30, 2019, were $2.4 billion, an increase of 3.8% compared with the first quarter of 2018. The 3.8% increase consisted of 6.6% growth in local currencies and a 2.8% decline related to foreign currency exchange. In local currencies, internally generated sales increased 4.3% and acquisition growth was 2.3%. Excluding approximately $15.0 million in corporate revenues from product sales to Covetrus under the transition services agreement entered into in connection with the Animal Health spin-off, normalized internal sales growth in local currencies was 3.7% (see Exhibit A for details of sales growth and a reconciliation of this non-GAAP measure to GAAP sales).

Net income attributable to Henry Schein, Inc. from continuing operations for the first quarter of 2019 was $118.4 million, or $0.78 per diluted share, compared with prior-year net income from continuing operations of $111.5 million, or $0.72 per diluted share. Non-GAAP net income from continuing operations for the first quarter of 2019 was $120.6 million, or $0.80 per diluted share, compared with non-GAAP net income from continuing operations of $113.6 million, or $0.74 per diluted share, for the first quarter of 2018. Non-GAAP results for the first quarter of 2019 and 2018 exclude certain items noted in Exhibit B, which provides a reconciliation of GAAP net income from continuing operations and diluted EPS from continuing operations to non-GAAP net income and diluted EPS from continuing operations.

“We are pleased with our performance to date as we execute on our 2018 to 2020 strategic plan. We have completed the first quarter of what we have characterized as a transition year as we continue to separate operations of our former Animal Health business. Throughout this transition, we believe we gained market share in both of our global Dental and Medical businesses, and are confident that Henry Schein is well-positioned for operational success over the long-term,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein.

“We will continue to focus on supporting our customers around the world with the broadest array of products and services, along with innovative technology that expands our value-added solutions offering while pursuing new investment opportunities,” Mr. Bergman continued.

Dental sales of $1.5 billion decreased 0.1%, consisting of 3.8% growth in local currencies and a 3.9% decline related to foreign currency exchange. In local currencies, internally generated sales increased 3.2% and acquisition growth was 0.6%. The 3.2% internal growth in local currencies included 2.7% growth in North America and 4.0% growth internationally.

“First quarter dental consumables internal sales growth in North America was 2.5%, reflecting modest market-share gains in a stable end market. Dental equipment internal sales growth of 3.3% in local currencies improved sequentially, driven by double-digit growth in CAD/CAM equipment sales,” commented Mr. Bergman. “Internationally, dental consumables internal sales in local currencies had robust growth of 5.5%. Dental equipment internal sales in local currencies declined by 1.2%, due largely to the timing of the International Dental Show (IDS) in Cologne, Germany, in March, which customarily results in lower international equipment sales in the first quarter that typically accelerate in the second quarter.”

Medical sales of $683.7 million increased 6.8%, consisting of 7.0% growth in local currencies and a 0.2% decline related to foreign currency exchange. In local currencies, internally generated sales increased 5.1% and acquisition growth was 1.9%.

“We were pleased with Medical internal sales growth of 5.1% in local currencies during the first quarter, despite a fairly light influenza season that adversely impacted patient office visits,” remarked Mr. Bergman. “We are well-positioned in our partnerships with large group practices, independent physician offices, and alternate sites of care, which are driving our continued market-share gains.”

Technology and Value-Added Services sales from continuing operations of $115.5 million increased 35.1%, consisting of 36.8% growth in local currencies and a 1.7% decline related to foreign currency exchange. In local currencies, internally generated sales increased 2.1% and acquisition growth was 34.7%.

“Technology and Value-Added Services growth in the first quarter was primarily driven by the formation of Henry Schein One. North America internal sales growth in local currencies was 0.9%. Internal sales increased by 7.0% in local currencies in our international business. With a single connected platform in Henry Schein One, we are helping our customers leverage technology solutions to automate tasks, share data, and better communicate with their patients. We expect these solutions will drive long-term growth in our technology, as well as our distribution businesses,” said Mr. Bergman.

Stock Repurchase Plan

The Company repurchased approximately 2.5 million shares of its common stock during the first quarter at an average price of $59.45 per share, or a total of approximately $150 million. The impact of the repurchase of shares on first quarter 2019 diluted EPS was immaterial. At the end of the first quarter of 2019, Henry Schein had approximately $250 million authorized and available for future stock repurchases.

Restructuring Program

Henry Schein previously disclosed a comprehensive restructuring initiative designed to increase profitability by improving business efficiencies, reducing redundancies and maximizing the Company's infrastructure. The Company recorded a pretax restructuring charge in the first quarter of 2019 of $4.6 million, or $0.02 per diluted share. These charges primarily include severance pay, facility closing costs, and outside professional and consulting fees directly related to the restructuring.

2019 EPS Guidance

Henry Schein today raises 2019 non-GAAP financial guidance. At this time the Company is not providing GAAP guidance as it is unable to provide an accurate estimate of costs related to its restructuring initiative on full-year 2019 financial results. Guidance is as follows:

• 2019 non-GAAP diluted EPS from continuing operations attributable to Henry Schein, Inc. is expected to be $3.38 to $3.50, reflecting growth of 7% to 10% compared with 2018 non-GAAP diluted EPS from continuing operations of $3.17. This compares to prior guidance of $3.38 to $3.46, reflecting growth of 7% to 9%. The Company’s Animal Health business was spun off to shareholders as of February 7, 2019, and that business is classified as a discontinued operation for all current and prior periods presented.

• Guidance for 2019 non-GAAP diluted EPS attributable to Henry Schein, Inc. is for current continuing operations as well as completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any. Guidance also assumes foreign exchange rates that are generally consistent with current levels.

The Company has provided guidance for 2019 diluted EPS on a non-GAAP basis as noted above. A reconciliation to the Company’s projected 2019 diluted EPS prepared on a GAAP basis is not provided because the Company is unable to provide such reconciliation for an estimate of restructuring costs without unreasonable effort. The inability to provide a reconciliation is due to the uncertainty and inherent difficulty predicting the occurrence, the financial impact, and the periods in which the non-GAAP adjustments may be recognized.

The Company’s 2019 diluted EPS prepared on a GAAP basis will include the impact of such items as restructuring charges and any litigation settlement expenses and the tax effect of all such items. Management does not believe these items are representative of the Company’s underlying business performance. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

First Quarter 2019 Conference Call Webcast

The Company will hold a conference call to discuss first quarter 2019 financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call through Henry Schein’s website at www.henryschein.com. In addition, a replay will be available beginning shortly after the call has ended.

BISCO is happy to introduce TheraCal PT, a biocompatible, dual-cured, resin-modified calcium silicate designed for pulpotomy treatment. TheraCal PT maintains tooth vitality by performing as a barrier and protectant of the dental pulpal complex.

TheraCal PT’s chemical formulation consists of synthetic Portland Cement calcium silicate particles in a unique hydrophilic matrix which facilitates calcium release. TheraCal PT is radiopaque allowing for easy identification and differentiation from recurrent decay and other restorative materials. TheraCal PT’s physical properties resist breakdown and degradation leading to a durable seal. TheraCal PT is also indicated for direct and indirect pulp capping (liner) and as a base.

BISCO’s THERA brand includes TheraCal LC, TheraCem and now TheraCal PT. BISCO believes that better dentistry can be achieved when practicing the THERA way.

For more information, call 800-247-3368 or visit www.bisco.com.

ATLANTA, May 7, 2019 /PRNewswire/ -- Georgia School of Orthodontics (GSO) announced that it has appointed John W. Stockstill, D.D.S., M.S. as the new Director of Research. Dr. Stockstill currently serves as Assistant Director of Research at GSO, and has played a crucial role in the development and success of the School's Institute for Orthodontic and Dentofacial Orthopedic Research.  In his role as Director of Research, he will continue to strengthen the School's Research Institute by overseeing the execution of all research projects, and applying the data to deliver superior patient care and improve the orthodontic industry.

A Diplomate of the American Board of Orthodontics, Dr. Stockstill has edited, authored and co-authored numerous scientific journals and textbooks, holds patents for orthodontic instruments, and has presented orthodontic lectures at the local, regional and international levels. He is a Fellow in the Academy of General Dentistry, American College of Dentists, and International College of Dentists, a member of Omicron Kappa Upsilon (Alpha-Alpha chapter), and a Diplomate of the American Board of Orthodontics.

Dr. Stockstill also serves as the Associate Editor of the American Journal of Orthodontics & Dentofacial Orthopedics. He is a past Chairman of the American Dental Education Association (ADEA) Special Interest Group for Temporomandibular Disorders/Orofacial Pain and is a founding member of the Association of University Temporomandibular Disorder/Orofacial Pain Programs.

GSO's previous Director of Research, Dr. Nandakumar Janakiraman, will now serve as Program Director at University of Louisville's Orthodontic Residency Program.

"We are privileged that Dr. Stockstill will continue to play a pivotal role in our Research Institute. His reputation for excellence, experience, and passion for orthodontic research will continue to guide the Department successfully into the future," said Ricky E. Harrell, D.M.D., M.A., GSO's program director.  "We would also like to congratulate Dr. Janakiraman on his esteemed appointment as Program Director of University of Louisville, and wish him great success in his future endeavors."

About Georgia School of Orthodontics

Georgia School of Orthodontics (GSO), based in Atlanta, GA, offers an advanced specialty education program in orthodontics and dentofacial orthopedics. The 36-month residency program is structured to provide collaborative and evidence-based learning for residents while providing quality orthodontic care to patients in the School's two patient clinics in metro Atlanta. GSO's mission is to educate outstanding dentists to be proficient in the clinical specialty of orthodontics, while providing Georgians with the highest level of patient care available. GSO faculty and staff are dedicated to diversity in both education and practice. For more information about GSO, visit GSOrthodontics.org. To schedule a complimentary consultation, visit bracestoday.com or call 770.351.7737.